Clinical Trial Update: Open-Label Study of TPI 287 for Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The open-label Phase 1/2 trial of TPI-287 for metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TPI-287

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN